Preclinical development of MK‐2214 a novel antibody targeting pS413 tau for the treatment of Alzheimer’s Disease
MK-2214是一种靶向pS413 tau的新型抗体,目前正处于治疗阿尔茨海默病的临床前开发阶段。
期刊:Toxicologic Pathology
影响因子:
doi:10.1177/0192623312467102
Elmore, Susan A; Berridge, Brian R; Boyle, Michael C; Cora, Michelle C; Hoenerhoff, Mark J; Kooistra, Linda; Laast, Victoria A; Morrison, James P; Rao, Deepa; Rinke, Matthias; Yoshizawa, Katsuhiko; Sugam, Jonathan A; Robey, Seth; Suon, Sokreine; Tian, Yuan; Wong, Oitak; Zhao, Xuemei; Chen, Ying; Judo, Michael; Smith, Brad E; Popescu, Andrei; Kurz, Jonathan; Herring, W Joseph; Baker, Jeanne; Parmentier‐Batteur, Sophie; Klein, Rebecca M; Smith, Sean M; Uslaner, Jason M